ProQR Therapeutics (PRQR) Total Non-Current Liabilities (2021 - 2025)

ProQR Therapeutics' Total Non-Current Liabilities history spans 4 years, with the latest figure at $43.3 million for Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities fell 35.43% year-over-year to $43.3 million; the TTM value through Dec 2024 reached $43.3 million, down 35.43%, while the annual FY2024 figure was $43.8 million, 34.95% down from the prior year.
  • Total Non-Current Liabilities for Q4 2024 was $43.3 million at ProQR Therapeutics, down from $67.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $85.3 million in Q4 2022 and bottomed at $43.3 million in Q4 2024.
  • The 4-year median for Total Non-Current Liabilities is $72.8 million (2023), against an average of $68.6 million.
  • The largest annual shift saw Total Non-Current Liabilities grew 8.51% in 2022 before it plummeted 35.43% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $78.7 million in 2021, then rose by 8.51% to $85.3 million in 2022, then dropped by 21.47% to $67.0 million in 2023, then plummeted by 35.43% to $43.3 million in 2024.
  • Per Business Quant, the three most recent readings for PRQR's Total Non-Current Liabilities are $43.3 million (Q4 2024), $67.0 million (Q4 2023), and $85.3 million (Q4 2022).